Loading
A phase 1/2 trial of PRGN-2012 - Phase I; Dose Level 1 in rare cancers of childhood, run by Precigen, Inc, active and no longer recruiting.
Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis is a phase 1/2 interventional study registered as NCT04724980 by Precigen, Inc, with 38 participants enrolled, started 2021-03-16 and due to reach its primary completion in 2024-06-05. Interventions recorded: PRGN-2012 - Phase I; Dose Level 1, PRGN-2012 - Phase I; Dose Level 2 and PRGN-2012 - Phase II; Dose Level 2.
Shares Precigen and the tag pipeline.
Shares Rare cancers of childhood (NCI PDQ umbrella) and the tag pipeline.